102 results about "Cell Surface Antigens" patented technology

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.

The present invention provides a combination of (i) an immune checkpoint modulator and (ii) a T-cell redirecting multifunctional antibody, or an antigen binding fragment thereof, for use in therapeutic treatment of a cancer disease. The T-cell redirecting multifunctional antibody comprises (a) a specificity against a T cell surface antigen; (b) a specificity against a cancer- and / or tumor-associated antigen; and (c) a binding site for human FcγRI, FcγRIIa and / or FcγRIII, wherein the antibody, or the antigen binding fragment thereof, binds with a higher affinity to human FcγRI, FcγRIIa and / or FcγRIII than to human FcγRIIb.

The invention provides an antibody for resisting CD19 on the surface of a porcine B cell or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, the invention provides an anti-porcine B cell surface CD19 antibody or an antigen binding fragment thereof, which can effectively bind to CD19 on the porcine B cell surface. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment thereof, and the antibody drug conjugate can be applied to screening of porcine B cells and marking of CD19 antigens on the surfaces of the porcine B cells, and has a good application prospect.

The present invention relates to a novel identified stem cell vMSC having angiogenesis characteristics, the vMSCs identified after being cultured under the culture conditions of the present invention are different from existing MSCs, are novel MSCs expressing CD141 cell surface antigens, have excellent cell expansibility, have an effect of directly forming blood vessels, have a paracrine effect of other MSCs, and are different from existing stem cells. The stem cell therapeutic agent for revascularization has a higher survival rate and a higher residual rate in tissues than conventional stem cell therapeutic agents, and can be used as a stem cell therapeutic agent for revascularization in which blood vessels are directly formed.

The invention belongs to the technical field of biology, and particularly relates to a preparation method of macaca fascicularis liver tissue single-cell suspension. The method comprises the following steps: cleaning macaca fascicularis liver tissues with a pre-cooling buffer solution, and processing into tissue fragments; mixing the tissue fragments with a digestion solution, wherein the digestion solution comprises collagenase I with the final concentration of 1 + / -0.2 mg / ml, collagenase II with the final concentration of 1 + / -0.2 mg / ml, bovine serum albumin with the final concentration of 0.04 + / -0.01% (w / v), DNase I with the final concentration of 10 + / -2 U / ml and the balance of a buffer solution; oscillating and incubating for 30 + / -10min under the conditions of 37 + / -2 DEG C and 150 + / -50rpm, and performing tissue digestion; centrifuging the digested suspension, removing the supernatant, resuspending with a buffer solution, and filtering with a cell sieve to obtain a single-cell primary suspension; and carrying out red blood cell lysis, washing and resuspension on the single-cell primary suspension to prepare the cynomolgus monkey liver tissue single-cell suspension. The method significantly improves the tissue dissociation efficiency, reduces cell adhesion and fragments, effectively protects cell surface antigen epitopes, and has the advantages of simple operation, economy and high efficiency.

The present invention provides a low pH pharmaceutical composition comprising (a) an antibody constructs comprising a first domain binding to a target cell surface antigen, a second domain binding to a second antigen and preferably a third domain, which is a specific Fc modality, (b) at least one buffer agent, (c) at least one saccharide, and (d) at least one surfactant; and wherein the pH of the pharmaceutical composition is in the range of 3.5 to 6.

The present invention relates to epitopes of leucine-rich immunoglobulin-like domain 1 (Lrig-1), an antigen present on the surface of regulatory T cells, and antibodies or antigen-binding fragments that specifically bind thereto.

The application discloses a detection method of cell surface antigens and application thereof, and relates to the detection field. The detection method of cell surface antigens comprises the following steps: mixing liposome-treated cells to be detected with capture microspheres and fluorescent microspheres, detecting the fluorescence intensity, and analyzing the expression of cell surface antigens. The surface of the capture microspheres is coated with a first antibody against a specific antigen on the surface of target cells. The surface of the fluorescent microspheres is coated with a second antibody against a target antigen on the surface of target cells. The detection method has low cost and can be used for directly quantitatively and qualitatively analyzing the expression of surface antigens of specific types of cells.

The present invention relates to agents and methods for targeted delivery of a payload to a cell. The payload comprises various molecules, such as therapeutic or diagnostic agents, in particular toxins, immunomodulators or radiodiagnostic agents. In some embodiments, the invention relates to providing a subject with a compound comprising a payload moiety and at least two tags (tag conjugates) and a compound (docking compound) that binds to the tags of the tag conjugates and a target antigen (e.g., a cell surface antigen on a target cell).

The invention provides an antibody for resisting CD19 on the surface of a porcine B cell or an antigen binding fragment thereof as well as a composition and application thereof. Specifically, the invention provides an anti-porcine B cell surface CD19 antibody or an antigen binding fragment thereof, which can effectively bind to CD19 on the porcine B cell surface. The invention also provides an antibody drug conjugate containing the antibody or the antigen binding fragment thereof, and the antibody drug conjugate can be applied to screening of porcine B cells and marking of CD19 antigens on the surfaces of the porcine B cells, and has a good application prospect.

The present disclosure provides a low pH pharmaceutical composition comprising (a) an antibody constructs comprising a first domain binding to a target cell surface antigen, a second domain binding to a second antigen and preferably a third domain, which is a specific Fc modality, (b) at least one buffer agent, (c) at least one saccharide, and (d) at least one surfactant; and wherein the pH of the pharmaceutical composition is in the range of 3.5 to 6.

A fusion antibody and its application. The fusion antibody includes: a) IL-15; b) IL-15Ra; and c) an antibody targeting a therapeutically relevant cell surface antigen. The antibody includes a heavy chain variable region (VH), a heavy chain constant region (CH1), a light chain variable region (VL), and a light chain constant region (CL). IL-15 / IL-15Ra is located between the C-terminus of the heavy chain variable region VH and the N-terminus of the heavy chain constant region CH1, and between the C-terminus of the light chain variable region VL and the N-terminus of the light chain constant region CL. This fusion antibody prolongs its half-life and, utilizing its targeting properties, specifically reaches its target site to exert its effect, conferring IL-15 with unique cell targeting properties. It exerts its receptor activation effect only in an environment containing high receptor concentrations of IL-2βγ, thus reducing the systemic toxicity of the IL-15 / IL-15Ra complex.

A nanoparticle for delivery of mRNA to cell, comprising a core comprising a polyethylenimine polymer having fluorinated groups covalently coupled thereto and with mRNA reversibly associated therewith, and a shell surrounding the core comprising heparin. Ij some embodiments, the nanoparticle comprises a targeting agent associated with the shell, wherein the targeting agent is selected from the group consisting of agents that bind to receptors overexpressed on tumor cells, agents that bind to cell surf ace antigens that are expressed on pluripotent stem cells, agents that bind to cell surface antigens on T cells, and agents that bind to antigens presented by MHO molecules. Pharmaceutical compositions that include the nanoparticle and methods for using the nanoparticle for transfecting cells are provided

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector for specifically targeting a target cell and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen targeting artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Moreton vesicular disease virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Moreton vesicular disease virus envelope, provided by the invention, can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed based on mutated Moreton vesicular disease virus envelope protein is better in stability in serum, and has a good application prospect. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

The present invention relates to a newly identified secretion group of vMSCs and uses thereof, different from existing MSCs, the vMSCs of the present invention obtained by culturing under specific culture conditions are novel MSCs expressing a CD141 cell surface antigen, the composition of the secretion group secreted by the vMSCs is different from that of the existing MSCs, and the secretion group significantly increases vascular budding of other stem cells, and has a significant increase in blood vessel germination rate. Therefore, the compound can be used for promoting angiogenesis of stem cells and for preventing or treating vascular diseases or vascular dysfunction.

The present invention relates to polypeptides comprising a membrane surface domain and uses thereof. In particular, the present invention provides an engineered polypeptide comprising a membrane surface domain comprising an extracellular domain of a B cell surface antigen or a variant thereof.

The present invention provides a fusion protein for activating an immune cell to kill a tumor cell, and a recombinant virus and a use thereof. The fusion protein comprises an extracellular domain, a hinge region, a transmembrane domain, and an intracellular domain, wherein the extracellular domain is a polypeptide or an active fragment thereof that specifically binds to an immune cell surface antigen, and a killing function of the immune cell is activated by specifically binding to the immune cell surface antigen; and the transmembrane domain is a polypeptide for anchoring the fusion protein on a cell membrane of the tumor cell. The fusion protein and recombinant virus of the present invention can effectively kill the tumor cell and have broad-spectrum killing activity against various tumors.

The present invention relates to antibodies or antigen-binding fragments that specifically bind to an epitope of a Lrig-1 (leucine-rich and immunoglobulin-like domain 1) protein, said Lrig-1 protein being an antigen present on the surface of regulatory T cells. The antibody or antigen-binding fragment specifically binding to the epitope of the Lrig-1 protein according to the present invention specifically binds to the epitope of the present invention existing in regulatory T cells, thereby regulating the function of regulatory T cells, maintaining or enhancing the activity of effector T cells, and can be very effectively used in the prevention, amelioration or treatment of various diseases.

The present invention addresses the problem of providing a cell population isolated from a living body, which contains mesenchymal cells that have a prescribed cell surface antigen molecule and can be used in the production of a cell sheet. A cell population that is isolated from a living body and contains 80% or more of mesenchymal cells that express at least one type of cell surface antigen molecule selected from the group consisting of CD13, CD59, CD49e, CD151 and CD280 is used. The mesenchymal cells are preselected from cells collected from tissues in the oral cavity or a culture thereof, and preferably express at least three or more types of cell surface antigen molecules selected from the group consisting of CD13, CD59, CD49e, CD151, and CD280.

A cell processing platform and method for selective isolation and activation of target cells, such as T-cells, NK-cells, and hematopoietic stem cells, from a biological sample. The platform employs aptamer-functionalized microbubbles, which selectively bind to target cell surface antigens to create buoyant target cell-microbubble complexes. A centrifugation module separates buoyant target cells from non-target cells by exploiting their distinct buoyancy properties. The system includes advanced aptamer designs, such as Locked Nucleic Acid (LNA) modifications, temperature-controlled folding buffers, and reversible binding mechanisms using complementary strands or enzymatic cleavage to release target cells. Additional features include optimized spacer configurations to enhance binding accessibility and aptamer stability for high specificity and yield. This platform also enables selective removal of senescent cells using aptamer-functionalized microbubbles, facilitating continuous processing and supporting applications in cell therapy, research, and regenerative medicine.

The present invention relates to a membrane surface domain-containing polypeptide and uses thereof. Specifically, the present invention provides an engineered polypeptide comprising a membrane surface domain comprising an extracellular domain of a B cell surface antigen or a variant thereof.

Disclosed are compositions of lipid nanoparticles (LNP) comprising an ionizable cationic lipid, a phospholipid, a sterol, and a PEG-lipid (non-functionalized and optionally functionalized). The functionalized PEG-lipid can be conjugated with a binding moiety to create a targeted LNP (tLNP). The disclosed tLNP preferentially deliver a nucleic acid molecule or other negatively charged payload to cells expressing a cell surface antigen recognized by the binding moiety of the tLNP, and are better tolerated, as compared to LNPs and tLNPs comprising ionizable cationic lipids found in marketed pharmaceuticals comprising LNPs.

A fusion antibody and a use thereof. The fusion antibody comprises: a) IL-15; b) IL-15Ra; and c) an antibody for targeted therapy against associated cell surface antigens, wherein the antibody comprises a heavy chain variable region VH, a heavy chain constant region CH1, a light chain variable region VL and a light chain constant region CL; IL-15 / IL-15Ra is located between a C terminal of the heavy chain variable region VH of the antibody and a N terminal of the heavy chain constant region CH1 of the antibody, and IL-15 / IL-15Ra is located between a C terminal of the light chain variable region VL of the antibody and a N terminal of the light chain constant region CL of the antibody. The fusion antibody can prolong a half-life period thereof and can use the targeting property of the antibody to specifically reach the site of action to exert the effect thereof, conferring specific cell targeting to IL-15. IL-15 can only exert the receptor activation effect thereof in an environment with high receptor concentrations of IL-2βγ, thereby reducing the systemic toxicity of an IL-15 / IL-15Ra complex.

The present invention relates to an immunomagnetic bead and its application in the separation of renal tubular epithelial cells, belonging to the technical field of immunoassay. The present invention provides an immunomagnetic bead for separating renal tubular epithelial cells in a sample. The immunomagnetic bead includes magnetic beads and antibodies conjugated to the magnetic beads. The antibodies can specifically bind to the surface antigens of renal tubular epithelial cells in the sample to achieve highly efficient capture of renal tubular epithelial cells. Using the immunomagnetic bead to separate renal tubular epithelial cells in the sample has the advantages of low cost, strong specificity, high separation purity, simple operation and high sensitivity. Moreover, the renal tubular epithelial cells sorted by the immunomagnetic bead have a high recovery rate and cell activity, and have little impact on downstream applications. Therefore, the separation of renal tubular epithelial cells in the sample by the immunomagnetic bead has great application prospects in clinical practice.

The invention discloses a tri-specific antigen binding protein, and relates to a tri-specific antibody specifically binding two tumor antigens GPRC5D and BCMA and a T cell surface antigen CD3, a pharmaceutical composition containing the tri-specific antibody, a preparation method and application.

The present disclosure generally relates to binding agents, such as antibodies and antigen binding fragments thereof, that are capable of binding to trophoblast cell surface antigen-2 (TROP2). Also disclosed herein are binding agents that are capable of targeting TROP2-expressing tumor cells and their use for the treatment of cancer. Single domain antibodies that specifically binds to amino acid residues of the extracellular domain of TROP2 are provided.

The present disclosure provides a therapeutic method of treating cancer metastasis by inducing clearance of EVs using a binding agent specific to an EV protein. The method utilizes one or more binding agents specific to EV proteins, where the EV proteins are selected from prostaglandin F2 receptor negative regulator (PTGFRN); basigin (BSG); immunoglobulin superfamily member 2 (IGSF2); immunoglobulin superfamily member 3 (IGSF3); immunoglobulin superfamily member 8 (IGSF8); integrin beta-1 (ITGB1); integrin alpha-4 (ITGA4); 4F2 cell-surface antigen heavy chain (SLC3A2); a class of ATP transporter proteins (ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B3, ATP2B1, ATP2B2, ATP2B3, ATP2B4); CD13 (aminopeptidase N); MME (neprilysin), ENPP1 (ectonucleotide pyrophosphatase / phosphodiesterase family member 1); and NRP1 (neuropilin-1). Further provided herein includes a pharmaceutical composition for the treatment of cancer metastasis.

The invention relates to the technical field of biological medicine, and discloses a lentiviral vector and a construction method and application thereof, the lentiviral vector comprises: (1) an antigen-targeted artificial protein receptor, the receptor comprising a target cell surface antigen binding domain and a transmembrane domain; (2) a mutated Maraba virus envelope protein; and (3) an expression cassette, wherein the expression cassette comprises a heterologous transgene. The novel lentiviral vector based on the mutated Maraba virus envelope provided by the invention can realize specific infection on target cells in vitro and in vivo, and compared with a vesicular stomatitis virus envelope VSV-G, the lentiviral vector constructed on the basis of the mutated Maraba virus envelope protein has better stability in serum, and can be used for preparing a novel lentiviral vector of the mutated Maraba virus envelope. The efficiency of specifically infecting target cells is higher, and the drug effect in a mouse tumor model is more prominent.

Compositions and methods are provided that enhance CAR T-cell therapy by providing an oncolytic virus engineered to direct expression and secretion of a multivalent adapter protein. The multivalent adapter protein targets both a broadly tumor-associated cell surface antigen and an antigen binding domain of a CAR T-cell.

Bispecific antibodies and combinations thereof for the treatment of proliferative disease are disclosed. The antibodies target cell surface antigens on immune cells. Methods of treatment of proliferative diseases, including cancers by administering the bispecific antibodies are further disclosed.